XML 55 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2020
May 31, 2018
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Concentration Risk [Line Items]                  
Revenue     $ 11,147 $ 12,853 $ 9,040 $ 21,893 $ 33,040 $ 53,163 $ 37,312
Accounts receivable               $ 35,986 $ 790
AbbVie Ireland Unlimited Company                  
Concentration Risk [Line Items]                  
Revenue $ 26,600 $ 9,900 2,972 6,775 1,751 8,526 11,498    
Amgen Inc                  
Concentration Risk [Line Items]                  
Revenue     337 357 2,237 2,594 2,931    
Astellas Pharma Inc.                  
Concentration Risk [Line Items]                  
Revenue     $ 5,880 $ 4,657 $ 4,766 $ 9,423 $ 15,303